Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

P1NP and TRACP-5b are expressed as median values.BMI body mass index, P1NP procollagen type 1 N-terminal propeptide, TRACP-5b tartrate-resistant acid phosphatase isoform 5b, eGFR estimated glomerular filtration rate, 25OHD 25-hydroxyvitamin D; Differences between the groups were determined by ANOVA or Fisher’s exact test.Demographic and clinical characteristics of subjects at baseline after extraction by propensity score matching.Denosumab (n = 69)Romosozumab (n = 69)P valueAge (years, mean ± SD)74.20 ± 11.3275.83 ± 9.700.367BMI (kg/m2)21.15 ± 3.3922.09 ± 3.240.192T-scoreLumbar spine − 2.50 ± 1.13 − 2.62 ± 1.250.322Total hip − 2.55 ± 0.73 − 2.57 ± 0.840.930Femoral neck − 3.12 ± 0.62 − 3.12 ± 0.820.870Prior vertebral fracture, n (%)26 (37.7)25 (36.2)1.000Prior non-vertebral fracture, n (%)12 (17.4)13 (18.8)1.000History of prior treatment, n (%)Naïve42 (60.9)49 (70.1)0.281Switch27 (39.1)20 (29.0)Concomitant use of active vitamin D, n (%)12 (17.4)35 (50.7)0.612PINP (µg/L, IQR)56.8 [35.9, 84.3]68.6 [41.3, 99.8]0.086TRACP-5b (mU/dL, IQR)454.0 [350.5, 621.5]545.0 [353.0, 690.0]0.296Serum albumin (g/dL)4.12 ± 0.294.17 ± 0.340.104Serum-corrected Ca (mg/dL)9.35 ± 0.479.34 ± 0.370.761eGFR (mL/min/1.73 m2)70.36 ± 21.4368.78 ± 21.90.47225OHD (ng/mL)15.00 ± 6.3216.35 ± 6.170.241Data are expressed as the mean ± standard deviation (SD) or the number (%) of subjects.

Source: Study proportions. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

From April 2015 to August 2020, this retrospective observational cohort study was conducted at our clinic and 4 affiliated institutions.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Denosumab versus romosozumab for postmenopausal osteoporosis treatment

Cohort study · Scientific Reports · 2021

Original publication title

Denosumab versus romosozumab for postmenopausal osteoporosis treatment

Tomonori Kobayakawa; Akiko Miyazaki; Makoto Saito; Takako Suzuki; Jun Takahashi; Yukio Nakamura

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment. However, no studies have directly compared their therapeutic effects or safety in postmenopausal osteoporosis. This retrospective observational registry study compared the efficacy of 12-month denosumab or romosozumab treatment in postmenopausal osteoporosis patients. The primary outcome was the change in bone mineral density (BMD) at the lumbar spine. Secondary outcomes included BMD changes at the total hip and femoral neck, changes in bone turnover markers, and adverse events.

Propensity score matching was employed to assemble patient groups with similar baseline characteristics. Sixty-nine patients each received either denosumab or romosozumab for 12 months. The mean 12-month percentage change from baseline in lumbar spine BMD was 7.2% in the denosumab group and 12.5% in the romosozumab group, indicating a significant difference between the groups. The percentage changes in BMD at both the total hip and femoral neck were also significantly higher at 12 months in the romosozumab group than in the denosumab group.

In denosumab patients, bone formation and bone resorption markers were significantly decreased at 6 and 12 months from baseline. In the romosozumab group, the bone formation marker was significantly increased at 6 months and then returned to baseline, while the bone resorption marker was significantly decreased at both time points. Adverse events were few and predominantly minor in both groups, with no remarkable difference in the incidence of new vertebral fractures. Romosozumab showed a higher potential for improving BMD than denosumab in this clinical study of postmenopausal osteoporosis patient treatment.

Authors’ abstract

Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment. However, no studies have directly compared their therapeutic effects or safety in postmenopausal osteoporosis. This retrospective observational registry study compared the efficacy of 12-month denosumab or romosozumab treatment in postmenopausal osteoporosis patients. The primary outcome was the change in bone mineral density (BMD) at the lumbar spine. Secondary outcomes included BMD changes at the total hip and femoral neck, changes in bone turnover markers, and adverse events.

Propensity score matching was employed to assemble patient groups with similar baseline characteristics. Sixty-nine patients each received either denosumab or romosozumab for 12 months. The mean 12-month percentage change from baseline in lumbar spine BMD was 7.2% in the denosumab group and 12.5% in the romosozumab group, indicating a significant difference between the groups. The percentage changes in BMD at both the total hip and femoral neck were also significantly higher at 12 months in the romosozumab group than in the denosumab group.

In denosumab patients, bone formation and bone resorption markers were significantly decreased at 6 and 12 months from baseline. In the romosozumab group, the bone formation marker was significantly increased at 6 months and then returned to baseline, while the bone resorption marker was significantly decreased at both time points. Adverse events were few and predominantly minor in both groups, with no remarkable difference in the incidence of new vertebral fractures. Romosozumab showed a higher potential for improving BMD than denosumab in this clinical study of postmenopausal osteoporosis patient treatment.

Publication and source details

Original title: Denosumab versus romosozumab for postmenopausal osteoporosis treatment

Tomonori Kobayakawa; Akiko Miyazaki; Makoto Saito; Takako Suzuki; Jun Takahashi; Yukio Nakamura

Scientific Reports · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T12:29:53.450780+00:00

DOI: 10.1038/s41598-021-91248-6 · PMC8175428